These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16701144)

  • 21. Clinical trials with recombinant allergens: research studies?
    Pauli G
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():257-64; discussion 264-5. PubMed ID: 20799469
    [No Abstract]   [Full Text] [Related]  

  • 22. Epicutaneous allergen administration: a novel approach for allergen-specific immunotherapy?
    Werfel T
    J Allergy Clin Immunol; 2009 Nov; 124(5):1003-4. PubMed ID: 19895988
    [No Abstract]   [Full Text] [Related]  

  • 23. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental forms of allergen immunotherapy with modified allergens and adjuvants.
    Mohapatra SS; San-Juan-Vergara H; Wopfner N; Ferreira F
    Clin Allergy Immunol; 2008; 21():393-413. PubMed ID: 18828519
    [No Abstract]   [Full Text] [Related]  

  • 25. Genetically modified allergens.
    Niederberger V; Valenta R
    Immunol Allergy Clin North Am; 2004 Nov; 24(4):727-38. PubMed ID: 15474868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transition of recombinant allergens from bench to clinical application.
    Cromwell O; Suck R; Kahlert H; Nandy A; Weber B; Fiebig H
    Methods; 2004 Mar; 32(3):300-12. PubMed ID: 14962765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of molecular biology on allergen immunotherapy.
    Bush RK
    Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):557-8. PubMed ID: 21030836
    [No Abstract]   [Full Text] [Related]  

  • 28. Preparing and mixing allergen vaccines for subcutaneous immunotherapy.
    Nelson HS
    Clin Allergy Immunol; 2008; 21():303-20. PubMed ID: 18828513
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines.
    Mascarell L; Van Overtvelt L; Moingeon P
    Immunol Allergy Clin North Am; 2006 May; 26(2):283-306, vii-viii. PubMed ID: 16701145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The immunological background of the allergen vaccines application].
    Rogala B
    Wiad Lek; 1999; 52(11-12):539-46. PubMed ID: 10745688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy.
    González-Rioja R; Ibarrola I; Arilla MC; Ferrer A; Mir A; Andreu C; Martínez A; Asturias JA
    J Allergy Clin Immunol; 2007 Sep; 120(3):602-9. PubMed ID: 17561242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
    Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
    Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allergen immunotherapy: where is it now?
    Nelson HS
    J Allergy Clin Immunol; 2007 Apr; 119(4):769-79. PubMed ID: 17337297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant allergens for immunotherapy. Where do we stand?
    Niederberger V; Valenta R
    Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):549-54. PubMed ID: 15640698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allergen vaccines for specific diagnosis.
    Larsen JN; Løwenstein H
    Clin Allergy Immunol; 2000; 15():1-51. PubMed ID: 10943287
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunological mechanisms of allergen-specific immunotherapy.
    Larché M; Akdis CA; Valenta R
    Nat Rev Immunol; 2006 Oct; 6(10):761-71. PubMed ID: 16998509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic and genetically engineered allergen derivatives for specific immunotherapy of type I allergy.
    Valenta R; Vrtala S; Focke-Tejkl M; Twardosz A; Swoboda I; Bugajska-Schretter A; Spitzauer S; Kraft D
    Clin Allergy Immunol; 2002; 16():495-517. PubMed ID: 11577556
    [No Abstract]   [Full Text] [Related]  

  • 38. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6.
    Linhart B; Mothes-Luksch N; Vrtala S; Kneidinger M; Valent P; Valenta R
    Biol Chem; 2008 Jul; 389(7):925-33. PubMed ID: 18627317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allergen-specific immunotherapy.
    Niederberger V
    Immunol Lett; 2009 Feb; 122(2):131-3. PubMed ID: 19100771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA vaccines for allergy treatment.
    Weiss R; Scheiblhofer S; Thalhamer J
    Methods Mol Med; 2006; 127():253-67. PubMed ID: 16988459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.